Why Agenus Stock Is Popping Today
An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.
AGEN earnings call for the period ending September 30, 2020.
Investor optimism is increasing ahead of an oral presentation at ESMO 2020.
AGEN earnings call for the period ending June 30, 2020.
The development-stage biopharma delivered two encouraging updates.
The immunotherapy company may be a diamond in the rough.
The biopharma company provided a clinical update for an important pipeline asset.
AGEN earnings call for the period ending March 31, 2020.
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
These clinical-stage drugmakers could be a steal at current levels.